Logo.png
IMUNON Reports 2023 Financial Results and Provides Business Update
28 mars 2024 08h00 HE | Imunon, Inc.
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
Study Evaluates Prev
Study Evaluates Prevalence of Four Recommended Practices for Suicide Prevention Following Hospital Discharge
12 mars 2024 11h15 HE | The Joint Commission
OAKBROOK TERRACE, Illinois, March 12, 2024 (GLOBE NEWSWIRE) -- Multiple studies suggest the risk for suicide is significantly higher following hospital discharge compared to during hospitalization....
Study Surmounts Barr
Study Surmounts Barrier to Measuring Healthcare Worker Exposure to Workplace Violence
27 févr. 2024 12h33 HE | The Joint Commission
OAKBROOK TERRACE, Illinois, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Workplace violence (WPV), including physical assaults and verbal threats, is a pervasive and significant issue for healthcare workers...
Logo.png
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
22 févr. 2024 08h00 HE | Imunon, Inc.
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
NOVARTIS logo.jpg
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
19 janv. 2024 10h00 HE | Novartis Pharma AG
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...
Global In Situ Hybridization Market
Global In Situ Hybridization Market Size, Share & Trends Analysis Report 2024-2030 - A $2.55 Billion Market by 2030, Technologies Empowering Personalized Treatment and COVID-19 Research
09 janv. 2024 14h23 HE | Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Global In Situ Hybridization Market Size, Share & Trends Analysis Report by Technology (FISH, CISH), Probe Type (DNA, RNA), Product (Instrument,...
NOVARTIS logo.jpg
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
05 janv. 2024 09h23 HE | Novartis Pharma AG
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the...
The Joint Commission
The Joint Commission Journal on Quality and Patient Safety publishes special issue on healthcare equity
04 janv. 2024 12h03 HE | The Joint Commission
OAKBROOK TERRACE, Illinois, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The Joint Commission Journal on Quality and Patient Safety (JQPS) today published a special 50th anniversary issue on healthcare equity....
Emergency department
Emergency department boarding’s impact on patient care and clinician well-being
28 nov. 2023 15h07 HE | The Joint Commission
OAKBROOK TERRACE, Illinois, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergency department (ED) boarding, or continuing to provide care for patients in the ED after the decision to admit due to lack of...